ASCM
ACAD icon

Adkins Seale Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Adkins Seale Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.59K Hold
300
– – 0.01% 209
2026
Q1 		$6.68K Hold
300
– – 0.01% 201
2025
Q4 		$8.01K Buy
+300
New +$7.17K 0.01% 199

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Adkins Seale Capital Management's ACAD Position: Q2 2026 in Review

Adkins Seale Capital Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 300 shares worth $7.59K. The position accounts for 0.01% of the portfolio, ranked #209.

Adkins Seale Capital Management first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.01K in Q4 2025. 346 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Adkins Seale Capital Management held 300 shares of Acadia Pharmaceuticals worth $7.59K as of Q2 2026.
  • Adkins Seale Capital Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up 0.01% of Adkins Seale Capital Management's portfolio in Q2 2026, its #209 holding.
  • Adkins Seale Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Adkins Seale Capital Management's Acadia Pharmaceuticals position peaked at $8.01K in Q4 2025.
  • 346 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Adkins Seale Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.